000			02087nam a2200469 i 4500
999			_c283598 _d283598
001			on1107669191
003			OCoLC
005			20190819135156.0
006			m o d f
007			cr bn||||a||||
008			190708s2019 dcu ob f000 0 eng c
040			_aPUCPR _beng _erda _epn _cGPO _dGPO _dMvI
042			_apcc
043			_an-us---
074			_a1008-I (online)
086	0		_aY 1.1/8:116-46
099			_aY 1.1/8:116-46
110	1		_aUnited States. _bCongress. _bHouse. _bCommittee on Energy and Commerce,
245	1	0	_aBringing Low-Cost Options and Competition while Keeping Incentives for New Generics Act of 2019 : _breport (to accompany H.R. 938) (including cost estimate of the Congressional Budget Office).
264		1	_a[Washington, D.C.] : _b[U.S. Government Publishing Office], _c[2019]
300			_a1 online resource (59 pages).
336			_btxt
337			_bc _2rdamedia
338			_bcr _2rdacarrier
490	1		_aReport / 116th Congress, 1st session, House of Representatives ; _v116-46
500			_a"May 2, 2019."
500			_aCRDP Program record.
504			_aIncludes bibliographical references.
588			_aDescription based on online resource, PDF version; title from title page (govinfo, viewed July 8, 2019).
776	0	8	_iPrint version: _aUnited States. Congress. House. Committee on Energy and Commerce. _tBringing Low-Cost Options and Competition while Keeping Incentives for New Generics Act of 2019 _w(OCoLC)1101904809
810	1		_aUnited States. _bCongress. _bHouse. _tReport ; _v116-46.
856	4	0	_uhttps://purl.fdlp.gov/GPO/gpo122825
856	4	0	_uhttps://purl.fdlp.gov/GPO/gpo122826
050		4	_aKF32 _b.E55 2019g
650		0	_aPharmaceutical industry _zUnited States _xQuality control.
650		0	_aGeneric drugs _xStandards _zUnited States.
650		0	_aGeneric drugs _xEffectiveness _zUnited States.
650		0	_aGeneric drugs _xPrices.
650		0	_aDrugs _zUnited States _xCost effectiveness.
655		7	_aLegislative materials. _2lcgft
942			_2sudocs _c8